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Abstract
Background: Compared with viral vectors, nonviral vectors are less immunogenic, more stable,
safer and easier to replication for application in cancer gene therapy. However, nonviral gene
delivery system has not been extensively used because of the low transfection efficiency and the
short transgene expression, especially in vivo. It is desirable to develop a nonviral gene delivery
system that can support stable genomic integration and persistent gene expression in vivo. Here,
we used a composite nonviral gene delivery system consisting of the piggyBac (PB) transposon and
polyethylenimine (PEI) for long-term transgene expression in mouse ovarian tumors.
Methods:  A recombinant plasmid PB [Act-RFP, HSV-tk] encoding both the herpes simplex
thymidine kinase (HSV-tk) and the monomeric red fluorescent protein (mRFP1) under PB
transposon elements was constructed. This plasmid and the PBase plasmid were injected into
ovarian cancer tumor xenografts in mice by in vivo PEI system. The antitumor effects of HSV-tk/
ganciclovir (GCV) system were observed after intraperitoneal injection of GCV. Histological
analysis and TUNEL assay were performed on the cryostat sections of the tumor tissue.
Results: Plasmid construction was confirmed by PCR analysis combined with restrictive enzyme
digestion. mRFP1 expression could be visualized three weeks after the last transfection of pPB/TK
under fluorescence microscopy. After GCV admission, the tumor volume of PB/TK group was
significantly reduced and the tumor inhibitory rate was 81.96% contrasted against the 43.07% in the
TK group. Histological analysis showed that there were extensive necrosis and lymphocytes
infiltration in the tumor tissue of the PB/TK group but limited in the tissue of control group. TUNEL
assays suggested that the transfected cells were undergoing apoptosis after GCV admission in vivo.
Conclusion: Our results show that the nonviral gene delivery system coupling PB transposon with
PEI can be used as an efficient tool for gene therapy in ovarian cancer.
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Background
Gene therapy is a promising strategy for the treatment of
unresectable cancer. Non-viral gene transfer systems used
in cancer gene therapy are attractive because they are rela-
tively stable, safer, and easier to produce than viral vectors
[1]. Conventional nonviral gene transfer systems include
the direct tissue injection of DNA or transfection across
the cell membrane using liposomes, peptide delivery sys-
tems, or polymer vectors[2]. Among them, the polycation
polyethylenimine (PEI) have been extensively used for in
vivo gene delivery [3]. PEI combines strong DNA compac-
tion capacity with an intrinsic endosomolytic activity[4].
Recently studies showed that PEI derivatives can mediate
efficient gene delivery in several tumors, such as lym-
phoma [5], hepatocellular carcinoma [6], pancreatic
tumors [7], and ovarian carcinoma [8]. However, a signif-
icant drawback to PEI-mediated gene transfer delivery is
that there still is no persistent transgene expression as
there is no stable chromosomal integration [9]. The devel-
opment of nonviral gene-transfer technologies that can
support stable chromosomal integration and persistent
gene expression in vivo is desirable.
Transposon system is a major step in overcoming that bar-
rier as it is a technology that combines the advantages of
nonviral delivery with genomic integration and persistent
transgene expression. Transposon-derived sequences
account for more than 40% of the genome in humans and
mice [10,11], indicating the importance of transposition
in evolution. Their ability to deliver and integrate specific
genetic cargo into a host's chromosome has made trans-
posons so useful as a molecular genetic tool in inverte-
brate species, and now they has progressively become
more important as delivery vectors of therapeutic expres-
sion cassettes to treat human disease[12,13]. The main
advantages of transposon-mediated genetic cargo delivery
are: 1) Transgene in a chromosomally integrated transpo-
son can be persistent expressed; 2) Transposon lacks viral
sequences that could elicit unwanted immune or inflam-
matory responses [14]; 3) Some transposons have the
capacity to accommodate large size foreign genes[15,16].
One of the well characterized DNA transposon vector
used in mammals is the synthetic Sleeping Beauty (SB)
transposon system. So far, SB transposon has been used
successfully to mediate stable gene transfer and expression
in several mouse and human cells [17-19]. However, as a
transgene tool for therapeutic gene delivery in mammals,
SB transposons was limited due to the facts that exhibits
overproduction inhibition which limits in vivo activity
[20] and that had a limited capacity to carry DNA frag-
ments[21]. Recently, several other transposon vectors
have been tested for their potential to deliver therapeutic
genes, including Tol2[22], Frog Prince[23], and piggy-
Bac(PB)[15,24-27]. These vectors differ in their efficiency
of gene insertion, genetic cargo capacity, integration site
preferences, and effects on chromosomal stability. Among
them, PB, a functional DNA transposon from cabbage
looper moth Trichoplusia ni, now was the widely used one
in human gene therapy and mammalian mutagenesis. Wu
et al. found that PB is the most active transposons com-
pared with SB, Tol2 and Mos1. They also showed that PB
lacks of overproduction inhibition, which is advanta-
geous in preclinical development of transposon-based
gene therapy[26].
Moreover, Ding and coworkers designed a binary cotrans-
fection assay system consisting of both a donor plasmid
containing the transposon and a helper plasmid contain-
ing the transposase. The donor plasmid, named PB [Act-
RFP] DS, can carry multiple genes, which allows one to
perform complex transgenic experiments such as identify-
ing positive transgenic animals with the help of a visible
marker. Their studies showed that cotransfection of donor
plasmid and helper plasmid produced drug-resistant
clones on average 50-fold higher than donor plasmid
transfection alone, which confirmed that the enhanced
clone production was due to trans-position. They sug-
gested that the PB transposon can accommodate large for-
eign genes and readily mediate the introduction of foreign
genes up to 14 kb in length. Therefore it can be an efficient
transgenesis and insertional mutagenesis tool in mice and
other vertebrate organisms[15].
In the present work, we adopted this PB transposon sys-
tem carrying the herpes simplex thymidine kinase gene
(HSV-tk gene) and delivered it to ovarian tumor grafted
mice using PEI as the transfection reagent. The therapeutic
potential of this nonviral gene delivery system was evalu-
ated in an established mouse model of ovarian cancer.
This is the first demonstration that PB combined with PEI
as nonviral gene transfer system can be used as an efficient
transgene tool for gene therapy in ovarian cancer.
Methods
Tumor cell lines
The cell line SKOV3 established from a human ovarian
adenocarcinoma was obtained from the Shanghai Insti-
tute of Cell Biology of Chinese Academy of Sciences
(Shanghai, China). Cells were grown in McCoy's 5A
medium supplemented with 10% (V/V) fetal bovine sera,
100 U/mL of penicillin, and 100 mg/mL streptomycin (all
purchased from GIBCO BRL, Grand Island, New York,
USA). Cells were maintained at 37°C in a humidified
incubator containing 5% CO2  and cultures were split
twice per week.
Plasmid construction
The plasmid PB [Act-RFP]DS (pPB), containing the
mRFP1 expression cassette, and plasmid Act-
PBase(pPBase), containing PB transposase were kindly
provided by Xiaohui Wu (Institute of DevelopmentalBMC Cancer 2009, 9:126 http://www.biomedcentral.com/1471-2407/9/126
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Biology and Molecular Medicine, School of Life Sciences,
Fudan University, Shanghai, China). The plasmid pORF-
HSVtk encoding the HSV-tk gene was obtained from Invi-
vogen (San Diego, CA, USA). To generate the recom-
binant plasmid PB [Act-RFP, HSV-TK], named as pPB/TK,
we first amplified HSV-tk cDNA using the forward primer
5'-ATTGGATCCGCTCCGGTGCCCGTCAGTGG-3' and
the reverse primer 5'-CTAACTAGTTCAGTTAGCCTC-
CCCCATCTCC-3'. The PCR fragment was TA cloned into
pMD18-T Simple vector (Takara, Dalian, China) and sub-
cloned into BamHI-SpeI sites of PB [Act-RFP] DS. Plasmid
construction was identified by PCR analysis combined
with restriction enzyme digestion. The primer sequences
for HSV-tk were: forward primer, 5'-CCTGTGGTGCCTC-
CTGAACT-3'; reverse primer, 5'-GTTGCTATGGCCGCGA-
GAAC-3'. The predicted product size is 421 bp. For
mRFP1, the forward primer was 5'-GGACGGCGAGT-
TCATCTACA-3', and the reverse primer was 5'-TTGAC-
CTCGGCGTCGTAGTG-3', and the predicted product size
is 191 bp.
Tumor model
Animal study in this research has been performed with the
approval of Animal Ethics Committee of Obstetrics and Gyne-
cology Hospital, Fudan University. Female nude mice BALB/
c at 6 weeks old were purchased from the Animal Center
of the Chinese Academy of Science, Shanghai, China, and
maintained in specific pathogen-free facility. All proce-
dures were performed in accordance with The Guide for the
Ethical Treatment of Laboratory Animals from the Ministry
of Science and Technology of People's Republic of China
(Publication No. 2006-398). To generate ovarian cancer
tumor xenografts, SKOV3 cells (1 × 107 cells/0.1 ml of
medium/mouse) were inoculated subcutaneously in the
right flank of mice. Animals were inspected and weighed
every three days.
Complex formation and administration
In vivo-jetPEI was obtained from Polyplus-transfection
(Illkirch, France). PEI/DNA complexes were prepared as
follows: 3.2 μl of 150 mM PEI derivative in 5% glucose
solution were vortex mixed with 10 μg of pPB/TK DNA
and 10 μg of plasmid Act-PBase DNA in a final volume of
100 μl of 5% glucose solution. The glucosylated PEI/DNA
mixture (N/P ratio = 8) was left for 15 minutes at room
temperature, and then injected into xenografted mice
intratumorally.
Gene delivery to tumor in vivo
Transfection experiments were performed two weeks after
tumor inoculation. Twenty mice were assigned to four
groups: PB/TK treatment group (transfected with pPB/TK
Construction of recombinant Plasmid PB [Act-RFP, HSV-tk] Figure 1
Construction of recombinant Plasmid PB [Act-RFP, HSV-tk]. (A) PB [Act-RFP, HSV-tk] constructs. The HSV-tk gene 
was cloned in the BamHI-SpeI sites of the PB [Act-RFP] DS (pPB), generating PB [Act-RFP, HSV-tk] (pPB/TK), which consists of 
both HSV-tk and mRFP1 expression cassettes. PBL and PBR was a pair of PB repeat termini; (B) PB transposase helper con-
structs. The piggyBac transposase gene (PBase) driven by β-actin (Act) promoters was followed by rabbit β-globin polyA (rBG 
pA) (adapted from Ref [15]); (C) PCR analysis of pPB/TK: Lane 1: Marker; Lane 2: pPB/TK: PCR product of tk fragment; Lane 
3: pPB/TK: PCR product of mRFP1 fragment; Lane 4: pPB: PCR product of mRFP1 fragment; Lane 5: pORF-HSVtk: PCR prod-
uct of tk fragment; (D) Restriction analysis of pPB/TK: Lane 1: Marker; Lane 2: pPB/TK; Lane 3: pPB; Lane 4: pORF-HSVtk.BMC Cancer 2009, 9:126 http://www.biomedcentral.com/1471-2407/9/126
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and pPBase), PB group (transfected with pPB and
pPBase), TK group (transfected with pORF-HSVtk) and
control group (5% (vol/vol) dextrose). Each group con-
tained an equal number of large and intermediate-sized
tumors so that the mean tumor volume in each group was
comparable before intratumoral injection. Every mouse
was intratumorally injected with 100 μl PEI/DNA com-
plexes once a day on days 1, 4 and 7. Twenty-four hours
after the first transfection, 25 mg/kg ganciclovir (GCV)
was injected intraperitoneally twice daily for 7 days.
Tumor size was measured with calipers two times per
week, and tumor volume was estimated from two-dimen-
sional tumor measurements using the formula: V = length
(mm) × width2 (mm2)/2. Three weeks after the last trans-
fection in vivo, mice were euthanized and necropsies were
performed. The weights of tumors were measured to
determine the tumor weight (g) and inhibitory rate (%).
The tumor inhibitory rate was calculated using the follow-
ing formula: Inhibitory rate = [(tumor weight of control
group-tumor weight of experiment group)/tumor weight
of control group] × 100%. After measuring final tumor
weight, all tumors and major organs, such as heart, lung,
liver, spleen, kidney, were fixed in formalin and embed-
ded in paraffin for further sections. Histopathological
analysis was performed following routine hematoxylin
and eosin (H&E) staining on sections.
Assaying transgene expression
To monitor transgene expression, the mRFP1 reporter
gene was assessed in frozen tumor sections. Three weeks
after the last transfection of pPB/TK and intraperitoneal
injection of GCV, mice were scarified and formaldehyde-
fixed 6-μm frozen sections were rinsed in PBS and
mounted on glass slides. mRFP1 expression was visual-
ized using fluorescence microscopy (Nikon Eclipse E600,
Tokyo, Japan). Empty vector pPB combined with PEI was
used as control.
Immunofluorescence costaining
To examine the apoptosis of transfected cells, which was
induced by GCV in vivo, cryostat sections of tumors were
fixed with acetone and analyzed for TUNEL-positive cells
using a fluorescence in situ cell death detection kit (Roche
Molecular Biochemicals, Indianapolis, IN) according to
the manufacturer's instructions. In brief, sections were
treated with the TUNEL reaction mixture (including FITC-
conjugated dUTP) and incubated in the dark for 1.5 h at
37°C, followed by PBS washes. Sections were examined
using a fluorescence microscope.
Statistical analysis
Results are expressed as means ± SD. One-way ANOVA
was used to evaluate differences between groups, and a p
value less than 0.05 was considered significant.
Results
Recombinant plasmid construction
The HSV-tk gene was cloned within the BamHI-SpeI sites
of the PB transposon pPB, generating recombinant plas-
mid pPB/TK (10 kb) containing both mRFP1 and the
HSV-tk expression cassettes in Figure 1A. Figure 1B illus-
trates the helper plasmid which contains a PB transposase
gene (PBase) driven by β-actin (Act) promoters and fol-
lowed by rabbit β-globin polyA (rBG pA). Figure 1C
shows positive pPB/TK clones confirmed by PCR amplifi-
cation of the HSV-tk and mRFP1 genes fragments at 421
bp and 191 bp, respectively. We also confirmed the posi-
tive clone by restriction digest with HindIII. The correct
Tumor growth inhibition assay Figure 3
Tumor growth inhibition assay. Two weeks after subcu-
taneous inoculation of SKOV3 cells in BALB/c nude mice, 
complexes of pPB/TK, pPB, pORF-HSVtk with PEI were 
injected directly into the tumor three times (days 1, 4 and 7). 
GCV solution was administered by daily intraperitoneal injec-
tion beginning on the day after the first complex injections. 
Tumor volumes were monitored over time. Mice were sacri-
ficed 3 weeks after transfection in vivo. Errors bar represent 
the standard error of the mean.* p < 0.01, comparing the PB/
TK group with the control group at day 21.
Transgene expression in vivo Figure 2
Transgene expression in vivo. Fluorescence micrographs 
of pPB/TK-transfected tumor cryosections show that mRFP1 
expression was observed three weeks after transfection. 
Empty vector was used as control. (Magnification, ×200).BMC Cancer 2009, 9:126 http://www.biomedcentral.com/1471-2407/9/126
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clones of pPB/TK generated two fragments at 5.5 kb and
4.5 kb, while digestion of pPB or pORF-HSVtk yielded a
single band at 8.2 kb and 4.4 kb, respectively (Figure 1D).
Transposition mediates transgene expression in vivo
As mRFP1 is a marker for transgene expression, so mRFP1
expression in tumors was examined to ascertain whether
PB transposon-mediated gene transfer supports stable
gene expression in mice. The results indicated that the
mRFP1 expression could be observed even three weeks
after transfection on pPB/TK-transfected tumor cryosec-
tions, but not in empty vector controls (Figure 2).
Tumor growth inhibition after HSV-TK gene transfer and 
GCV administration
To test the in vivo sensitivity of the pPB/TK transfected cells
to GCV, the mice were cotransfected with pPB/TK and
pPBase using PEI, and subsequently treated with GCV.
Figure 3 shows that the tumor volume of PB/TK group was
significantly reduced, while much less tumor volume was
observed in the TK group. At day 21, the tumor inhibitory
rate in PB/TK group was 81.96% contrast to 43.07% in the
TK group (p < 0.01, Table 1). No difference in the rate was
observed between the PB group and control group. In all
animals, no noticeable toxicity was observed as no obvi-
ous damage on major organs was discovered by his-
topathological analysis (data not shown). The results
demonstrate that nonviral gene transfer by PB transposon
combined with PEI might result in potent tumor growth
inhibition.
Histological Analysis of different subgroups
To determine the antitumor efficacy of the HSV-tk/GCV
system in vivo, paraffin-embedded tissues were sectioned
at 4 μm and stained with H&E. The sections from the
tumor tissue of the PB/TK group showed extensive necro-
sis and lymphocyte infiltration, as shown in figure 4A.
Meanwhile, minimal necrosis and moderate lymphocyte
infiltration were identified in the TK group sections (Fig-
ure 4B). Necrosis was absent in tumor samples from both
the PB and control groups (Figure 4C, D).
In vivo killing of transfected cells by GCV
To evaluate the killing mechanism of transfected cells
treated with GCV, TUNEL assays were performed on
mouse tumor sections. Transfected cells were shown as
bright red with mRFP1 expression (Figure 5A), and apop-
totic cells were labeled with bright green (Figure 5B). The
merged image (yellow) suggested that almost all trans-
fected cells were undergoing apoptosis after GCV treat-
ment in vivo (Figure 5C).
Discussion
Ovarian carcinoma is a common cancer worldwide, and
there is still no effective therapy for such unresectable dis-
ease. Gene therapy may represent an attractive alternative
to the classical treatments, and numerous experimental
approaches have shown potential promise in treatment of
ovarian carcinoma [28-30]. Among them, several proto-
cols are based on the use of suicide genes such as the HSV-
tk gene, which can induce significant reduction in tumor
burden and can prolong survival after the prodrug GCV
treatment. However, the clinical application of this
H&E staining of tumor tissue samples removed from different  subgroups Figure 4
H&E staining of tumor tissue samples removed from 
different subgroups. PB/TK group: Extensive necrosis; TK 
group: Minimal necrosis but moderate lymphocyte aggrega-
tion around tumor cells; PB group & Control group: Enlarged 
hyperchromatic and pleomorphic nuclei with irregular 
nuclear membrane and nucleoli. (Magnification, ×200).
Table 1: Tumor weight on the 21st day after transfection in vivo
Group Weight of tumor (X ± SD, g) Tumor inhibitory rate (w/w,%)
PB/TK 0.31 ± 0.23 81.96 *
PB 1.61 ± 0.41 6.40
TK 0.98 ± 0.36 43.07
Control 1.72 ± 0.54
Growth inhibition was observed in the PB/TK group compared with the other groups. *p < 0.01, comparing the PB/TK group with the control 
group.BMC Cancer 2009, 9:126 http://www.biomedcentral.com/1471-2407/9/126
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approach may be hindered by transgene vectors. Current
viral vectors carry a risk for generating active viral particles
through recombination, and triggering unwanted host
inflammatory and immune responses [31,32], while non-
viral vectors lack the ability to induce stable chromosomal
integration and persistent gene expression in vivo [33].
In recent years there has been an increased understanding
of the mechanisms behind transgene delivery. Successful
delivery of foreign genes to a mammalian cell involves
several discrete steps: delivery of genes to target cells, cel-
lular entry, endosome escape, and integration into the
nucleus [34,35]. To date, no single gene transfer system
has been developed that can effectively fulfill the require-
ments for all of the features described above. A combina-
tion of complementary, multi-functional nonviral gene
transfer systems may satisfy the major requirements for
efficient gene delivery.
Cationic gene carriers have a net positive charge and can
facilitate the cellular entry of DNA by interacting with the
negatively charged cell surface [35,36]. Endosomal escape
is achieved by including components that induce mem-
brane fusion at low pH or block pH lowering inside the
endosome in the DNA-carrier complex. PEI is a cationic
polymer that serves as an effective vehicle for in vivo gene
delivery in many tissues. It facilitates effective DNA bind-
ing and protection, combined with the capability to
escape the endosome due to its proton buffering ability
with resultant osmotic swelling and endosomal disrup-
tion [36]. PEI has been shown to be an efficient transfec-
tion agent for ovarian carcinoma cells by Intraperitoneal
injection [8]. However, several studies indicated that PEI-
mediated transgene expression was dose-dependent and
transient, with maximal transgene expression observed
during the 48-hour period immediately following trans-
fection [37]. Very low amounts of DNA remained detect-
able after 72 h, indicating probable degradation and
clearance [8]. Thus, the development of nonviral gene-
transfer technologies that can support stable chromo-
somal integration and persistent gene expression in vivo is
desirable.
Transposon-mediated DNA delivery has opened the door
to the development of a new generation of vectors for
human gene therapy and mammalian [12]. Transposon-
based systems have been proven to be effective integrating
nonviral vectors that can mediate long-term in vivo trans-
gene expression [17]. Ohlfest and coworkers used SB
transposons as an intratumoral gene transfer vector for
glioblastoma multiforme, and delivered using PEI as gene
transfer reagent. They observed marked anti-tumor activ-
ity as demonstrated by reduced tumor vessel density, inhi-
bition of tumor growth, and tumor elimination in up to
50% of nude mice[38,39]. In the present study, we used
PB, a more active transposon[15,24-27], combined with
PEI to deliver HSV-TK gene into ovarian cancer xenografts.
Our results demonstrate that the expression of foreign
DNA mediated by PB transposon and PEI is much more
efficient than PEI alone. After HSV-TK gene transfer and
GCV administration, significant tumor growth inhibition
in vivo was observed up to 82%. The tumor inhibition
rate is much higher than previous study by SB mediated
gene therapy, probably due to PB transposon is more effi-
cient than SB transposon. Long-term expression and
bystander effect of HSV-TK gene may contribute to the
result. However, we still do not know the exact mecha-
nism how PB transposon could cause more tumor inhibi-
tion effect in vivo. Further studies should be considered to
determine how PB transposon performs in vivo in long
term studies. Furthermore, for PB transposon therapy to
transition into clinical consideration, the potential safety
issues from insertional disruption or deregulation in
genome will also need to be addressed.
Conclusion
In summary, our results demonstrate the feasibility and
effectiveness of a nonviral gene transfer system combind-
In vivo sensitivity of the HSV-tk transfected cells to GCV (Magnification, ×200) Figure 5
In vivo sensitivity of the HSV-tk transfected cells to GCV (Magnification, ×200). (A) The PB/TK transfected cells are 
shown as bright red. (B) Apoptotic cells are bright green after staining with TUNEL assay kit. (C) The merged cells (yellow) 
suggest the transfected cells were undergoing apoptosis after GCV treatment in vivo.BMC Cancer 2009, 9:126 http://www.biomedcentral.com/1471-2407/9/126
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ing the PB transposon with PEI. This system has shown
great efficiency on treating ovarian caner in our model,
however, the therapeutic effect of our method against
other carcinoma needs further investigation.
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